Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares OutstandingWages, Salaries and Other
Ratios

Revolution Medicines (RVMD) Accumulated Depreciation & Amortization: 2019-2025

Historic Accumulated Depreciation & Amortization for Revolution Medicines (RVMD) over the last 7 years, with Sep 2025 value amounting to $27.0 million.

  • Revolution Medicines' Accumulated Depreciation & Amortization rose 24.64% to $27.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $97.2 million, marking a year-over-year increase of 23.57%. This contributed to the annual value of $21.8 million for FY2024, which is 336.46% up from last year.
  • Latest data reveals that Revolution Medicines reported Accumulated Depreciation & Amortization of $27.0 million as of Q3 2025, which was up 7.94% from $25.0 million recorded in Q2 2025.
  • Over the past 5 years, Revolution Medicines' Accumulated Depreciation & Amortization peaked at $27.0 million during Q3 2025, and registered a low of $700,000 during Q1 2021.
  • Over the past 3 years, Revolution Medicines' median Accumulated Depreciation & Amortization value was $20.5 million (recorded in 2024), while the average stood at $20.6 million.
  • Data for Revolution Medicines' Accumulated Depreciation & Amortization shows a peak YoY soared of 1,769.89% (in 2023) over the last 5 years.
  • Revolution Medicines' Accumulated Depreciation & Amortization (Quarterly) stood at $800,000 in 2021, then soared by 50.00% to $1.2 million in 2022, then spiked by 1,374.50% to $17.7 million in 2023, then rose by 23.34% to $21.8 million in 2024, then grew by 24.64% to $27.0 million in 2025.
  • Its Accumulated Depreciation & Amortization stands at $27.0 million for Q3 2025, versus $25.0 million for Q2 2025 and $23.4 million for Q1 2025.